SCHEMBL3009031

SCHEMBL3009031

COc1cc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(Cl)cc4)CC3)n2)cc(OC)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
MAPT P10636 8/20 0.36
ALDH1A1 P00352 4/20 0.36
LMNA P02545 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
MAPK1 P28482 2/20 0.36
GAA P10253 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
RAB9A P51151 1/20 0.36
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011323 0.93 RAB9A (0.35) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3014556 0.92 MAPT (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3003810 0.92 GBA1 (0.40) MAPTALDH1A1KMT2ANPSR1SMN1; SMN2
SCHEMBL3002254 0.92 SMN1; SMN2 (0.42) MAPTALDH1A1LMNAKMT2AMAPK1
SCHEMBL3014057 0.91 MAPT (0.37) MAPTALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL3021608 0.91 MAPT (0.45) MAPTALDH1A1LMNAMAPK1SMN1; SMN2
SCHEMBL3011843 0.91 LMNA (0.37) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3016085 0.90 MAPT (0.39) MAPTALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL3020801 0.90 F2 (0.40) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3017369 0.90 RAB9A (0.36) MAPTSMN1; SMN2RAB9AHSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA PSEN1 14/4885PSEN2 23/4885APH1B 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.